G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.72 USD
-0.27 (-6.77%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $3.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.72 USD
-0.27 (-6.77%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $3.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum C VGM
Zacks News
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 22.22% and 15.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 182.35% and 49.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 17.19% and 22.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
G1 Therapeutics (GTHX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics (GTHX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.
G1 Therapeutics (GTHX)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for G1 Therapeutics (GTHX) points to a 149.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate G1 Therapeutics (GTHX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: G1 Therapeutics (GTHX) Q1 Earnings Expected to Decline
by Zacks Equity Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 8.74% and 6.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 2.91% and 12.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: G1 Therapeutics (GTHX) Q3 Earnings Expected to Decline
by Zacks Equity Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why G1 THERAPEUTICS (GTHX) is Poised for a Turnaround After Losing 16.4% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for G1 THERAPEUTICS (GTHX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.